PCOS and pregnancy: a review of available therapies to improve the outcome of pregnancy in women with polycystic ovary syndrome

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2749.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Bozdag G, Yapici Z, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27:3067–3073.
   PubMed Web of Science ®Google Scholar
• Puurunen J, Piltonen T, Morin-Papunen L, et al. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab. 2011;96:1827–1834.
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008;93:1276–1284.
   PubMed Web of Science ®Google Scholar
• Boyle JA, Cunningham J, O’Dea K, et al. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust. 2012;196:62–66.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li R, Qiao J, et al. Characteristics of abnormal menstrual cycle and polycystic ovary syndrome in community and hospital populations. Chin Med J. 2010;123:2185–2189.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687–708.
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo I, Younis JS. Basic research in PCOS: are we reaching new frontiers? Reprod Biomed Online. 2014;28:669–683.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Piperi C, Spina J, et al. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens). 2006;5:17–34.
   PubMedGoogle Scholar
• Teede HJ, Misso ML, Deeks AA, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. Med J Aust. 2011;195:S65–S112.
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans MJC, te Velde ER, et al. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77:91–97.
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
   PubMed Web of Science ®Google Scholar
• Ovulation induction in polycystic ovary syndrome. Current options – ScienceDirect. [ cited 2017 Sep 4]. Available from: http://www.sciencedirect.com/science/article/pii/S1521693416300736?via%3Dihub
   Google Scholar
• Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Joham AE, Paul E, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring). 2013;21:1526–1532.
   PubMed Web of Science ®Google Scholar
• Acién P, Quereda F, Matallín P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999;72:32–40.
   PubMed Web of Science ®Google Scholar
• Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol. 2004;103:219–224.
   PubMed Web of Science ®Google Scholar
• Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod. 1996;11:1884–1891.
   PubMed Web of Science ®Google Scholar
• Management of obesity. A national clinical guideline. SIGN. 2010. Available from: http://www.sign.ac.uk/assets/sign115.pdf
   Google Scholar
• Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring). 2009;17(Suppl 1):S1–70,v.
   PubMedGoogle Scholar
• Malik SM, Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes. 2012;3:71–79.
   PubMedGoogle Scholar
• Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641.
   PubMed Web of Science ®Google Scholar
• Nilsen RM, Vollset SE, Gjessing HK, et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr. 2006;84:1134–1141.
   PubMed Web of Science ®Google Scholar
• Johansson K, Cnattingius S, Näslund I, et al. Outcomes of pregnancy after bariatric surgery. N Engl J Med. 2015;372:814–824.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Palermo V, et al. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today. 2009;45:763–775.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eur J Endocrinol. 2010;162:193–212.
   PubMed Web of Science ®Google Scholar
• Baillargeon J-P, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893–902.
   PubMed Web of Science ®Google Scholar
• Fleming R, Hopkinson ZE, Wallace AM, et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002;87:569–574.
   PubMed Web of Science ®Google Scholar
• Oppelt PG, Mueller A, Jentsch K, et al. The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2010;118:633–637.
   PubMed Web of Science ®Google Scholar
• Hadžiomerović-Pekić D, Wildt L, Weiss JM, et al. Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril. 2010;94:2385–2388.
   PubMed Web of Science ®Google Scholar
• Cho LW, Kilpatrick ES, Keevil BG, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2009;70:233–237.
   PubMed Web of Science ®Google Scholar
• Falbo A, Rocca M, Russo T, et al. Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin. J Ovarian Res. 2010;3:16.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2009;4:CD003053.
   Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Electronic address: [email protected], Practice Committee of the American Society for Reproductive Medicine: role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017. DOI:10.1016/j.fertnstert.2017.06.026
   Google Scholar
• Matsuzaki T, Tungalagsuvd A, Iwasa T, et al. Clinical outcome of various metformin treatments for women with polycystic ovary syndrome. Reprod Med Biol. 2017;16:179–187.
   PubMedGoogle Scholar
• Sathyapalan T, Kilpatrick ES, Coady A-M, et al. Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2010;72:566–568.
   PubMed Web of Science ®Google Scholar
• Glintborg D, Andersen M. Thiazolinedione treatment in PCOS–an update. Gynecol Endocrinol. 2010;26:791–803.
   PubMed Web of Science ®Google Scholar
• Du Q, Yang S, Wang Y-J, et al. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Adv Ther. 2012;29:763–774.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang Y, Zheng S-Y, et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 2017;87:767–774.
   PubMed Web of Science ®Google Scholar
• Benjamin J, Nemetz H, Fux M, et al. Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res. 1997;31:489–495.
   PubMed Web of Science ®Google Scholar
• Huang LC, Fonteles MC, Houston DB, et al. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology. 1993;132:652–657.
   PubMed Web of Science ®Google Scholar
• Akiba S, Sato T. Cellular function of calcium-independent phospholipase A2. Biol Pharm Bull. 2004;27:1174–1178.
   PubMed Web of Science ®Google Scholar
• Bevilacqua A, Bizzarri M. Physiological role and clinical utility of inositols in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:129–139.
   PubMed Web of Science ®Google Scholar
• Artini PG, Di Berardino OM, Papini F, et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A Randomized Study. Gynecol Endocrinol. 2013;29:375–379.
   PubMed Web of Science ®Google Scholar
• Smith SD, Mikkelsen A, Lindenberg S. Development of human oocytes matured in vitro for 28 or 36 hours. Fertil Steril. 2000;73:541–544.
   PubMed Web of Science ®Google Scholar
• Bizzarri M, Cucina A, Dinicola S, et al. Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? Med Hypotheses. 2016;91:1–5.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314–1320.
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon J-P, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417–423.
   PubMedGoogle Scholar
• Gerli S, Papaleo E, Ferrari A, et al. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11:347–354.
   PubMed Web of Science ®Google Scholar
• Minozzi M, Costantino D, Guaraldi C, et al. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol. 2011;27:920–924.
   PubMed Web of Science ®Google Scholar
• Unfer V, Carlomagno G, Rizzo P, et al. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011;15:452–457.
   PubMed Web of Science ®Google Scholar
• Ciotta L, Stracquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci. 2011;15:509–514.
   PubMed Web of Science ®Google Scholar
• Papaleo E, Unfer V, Baillargeon J-P, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009;91:1750–1754.
   PubMed Web of Science ®Google Scholar
• Unfer V, Raffone E, Rizzo P, et al. Effect of a supplementation with myo-inositol plus melatonin on oocyte quality in women who failed to conceive in previous in vitro fertilization cycles for poor oocyte quality: a prospective, longitudinal, cohort study. Gynecol Endocrinol. 2011;27:857–861.
   PubMed Web of Science ®Google Scholar
• Colazingari S, Treglia M, Najjar R, et al. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288:1405–1411.
   PubMed Web of Science ®Google Scholar
• Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol. 2012;10:52.
   PubMed Web of Science ®Google Scholar
• Dell’Edera D, Sarlo F, Allegretti A, et al. The influence of D-chiro-inositol and D-myo-inositol in pregnant women with glucose intolerance. Biomed Rep. 2017;7:169–172.
   PubMed Web of Science ®Google Scholar
• Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.e25.
   PubMed Web of Science ®Google Scholar
• Kettel LM, Roseff SJ, Berga SL, et al. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril. 1993;59:532–538.
   PubMed Web of Science ®Google Scholar
• Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009;4:CD002249.
   PubMed Web of Science ®Google Scholar
• Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update. 1997;3:359–365.
   PubMed Web of Science ®Google Scholar
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–477.
   PubMed Web of Science ®Google Scholar
• Homburg R. Clomiphene citrate–end of an era? A mini-review. Hum Reprod. 2005;20:2043–2051.
   PubMed Web of Science ®Google Scholar
• Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab. 1998;83:2361–2365.
   PubMed Web of Science ®Google Scholar
• Weller A, Daniel S, Koren G, et al. The fetal safety of clomiphene citrate: a population-based retrospective cohort study. Bjog. 2017;124:1664–1670.
   PubMedGoogle Scholar
• Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–309.
   PubMed Web of Science ®Google Scholar
• Baruah J, Roy KK, Rahman SM, et al. Endometrial effects of letrozole and clomiphene citrate in women with polycystic ovary syndrome using spiral artery Doppler. Arch Gynecol Obstet. 2009;279:311–314.
   PubMed Web of Science ®Google Scholar
• Lee VCY, Ledger W. Aromatase inhibitors for ovulation induction and ovarian stimulation. Clin Endocrinol (Oxf). 2011;74:537–546.
   PubMed Web of Science ®Google Scholar
• Kar S. Current evidence supporting “letrozole” for ovulation induction. J Hum Reprod Sci. 2013;6:93–98.
   PubMedGoogle Scholar
• Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertility and Sterility. 2005;84:S95.
   Web of Science ®Google Scholar
• Davies MJ, Moore VM, Willson KJ, et al. Reproductive technologies and the risk of birth defects. N Engl J Med. 2012;366:1803–1813.
   PubMed Web of Science ®Google Scholar
• Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–129.
   PubMed Web of Science ®Google Scholar
• Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761–1765.
   PubMed Web of Science ®Google Scholar
• Orvieto R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril. 2009;91:1533–1535.
   PubMed Web of Science ®Google Scholar
• Hamilton-Fairley D, Kiddy D, Watson H, et al. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod. 1991;6:1095–1099.
   PubMed Web of Science ®Google Scholar
• Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update. 1999;5:493–499.
   PubMed Web of Science ®Google Scholar
• Cohlen BJ, Vandekerckhove P, te Velde ER, et al. Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men. Cochrane Database Syst Rev. 2000;2:CD000360.
   PubMedGoogle Scholar
• Veltman-Verhulst SM, Fauser BCJM, Eijkemans MJ. High singleton live birth rate confirmed after ovulation induction in women with anovulatory polycystic ovary syndrome: validation of a prediction model for clinical practice. Fertil Steril. 2012;98:761–768.e1.
   PubMed Web of Science ®Google Scholar
• Sekhon L, Shaia K, Santistevan A, et al. The cumulative dose of gonadotropins used for controlled ovarian stimulation does not influence the odds of embryonic aneuploidy in patients with normal ovarian response. J Assist Reprod Genet. 2017;34:749–758.
   PubMed Web of Science ®Google Scholar
• Barash OO, Hinckley MD, Rosenbluth EM, et al. High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer. Hum Reprod. 2017;32:2209–2217.
   PubMed Web of Science ®Google Scholar
• Kollmann M, Martins WP, Lima MLS, et al. Strategies for improving outcome of assisted reproduction in women with polycystic ovary syndrome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2016;48:709–718.
   PubMed Web of Science ®Google Scholar
• Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17–33.
   PubMed Web of Science ®Google Scholar
• Nastri CO, Ferriani RA, Rocha IA, et al. Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet. 2010;27:121–128.
   PubMed Web of Science ®Google Scholar
• Ortega-Hrepich C, Stoop D, Guzmán L, et al. A “freeze-all” embryo strategy after in vitro maturation: a novel approach in women with polycystic ovary syndrome? Fertil Steril. 2013;100:1002–1007.
   PubMed Web of Science ®Google Scholar
• Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012;2:CD008605.
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;11:CD006105.
   PubMed Web of Science ®Google Scholar
• Walls ML, Hunter T, Ryan JP, et al. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod. 2015;30:88–96.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-Setta AM. Are all human-derived follicle-stimulating hormone products the same? A systematic review and meta-analysis using direct and adjusted indirect analyses, to determine whether Fostimon® is more efficient than Metrodin-HP®. Gynecol Endocrinol. 2012;28:94–101.
   PubMed Web of Science ®Google Scholar
• Lainas TG, Sfontouris IA, Zorzovilis IZ, et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod. 2010;25:683–689.
   PubMed Web of Science ®Google Scholar
• Nastri CO, Teixeira DM, Moroni RM, et al. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45:377–393.
   PubMed Web of Science ®Google Scholar
• Dosouto C, Haahr T, Humaidan P. Gonadotropin-releasing hormone agonist (GnRHa) trigger – state of the art. Reproductive Biology. 2017;17:1–8.
   PubMed Web of Science ®Google Scholar
• Yen SS, Llerena O, Little B, et al. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab. 1968;28:1763–1767.
   PubMed Web of Science ®Google Scholar
• Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril. 2011;95:164–169.
   PubMed Web of Science ®Google Scholar
• Cerrillo M, Rodríguez S, Mayoral M, et al. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril. 2009;91:1526–1528.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Ejdrup Bredkjær H, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213–1220.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, et al. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006;13:173–178.
   PubMed Web of Science ®Google Scholar
• Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011;26:2593–2597.
   PubMed Web of Science ®Google Scholar
• Tang T, Glanville J, Orsi N, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006;21:1416–1425.
   PubMed Web of Science ®Google Scholar
• Chian R-C. In-vitro maturation of immature oocytes for infertile women with PCOS. Reprod Biomed Online. 2004;8:547–552.
   PubMed Web of Science ®Google Scholar
• Le Du A, Kadoch IJ, Bourcigaux N, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod. 2005;20:420–424.
   PubMed Web of Science ®Google Scholar
• Li Y, Feng H-L, Cao Y-J, et al. Confocal microscopic analysis of the spindle and chromosome configurations of human oocytes matured in vitro. Fertil Steril. 2006;85:827–832.
   PubMed Web of Science ®Google Scholar
• Siristatidis CS, Vrachnis N, Creatsa M, et al. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev. 2013;10:CD006606.
   PubMed Web of Science ®Google Scholar
• Nandi A, Sinha N, Ong E, et al. Is there a role for vitamin D in human reproduction? Horm Mol Biol Clin Investig. 2016;25:15–28.
   PubMed Web of Science ®Google Scholar
• Guler I, Himmetoglu O, Turp A, et al. Zinc and homocysteine levels in polycystic ovarian syndrome patients with insulin resistance. Biol Trace Elem Res. 2014;158:297–304.
   PubMed Web of Science ®Google Scholar
• Chakraborty P, Ghosh S, Goswami SK, et al. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res. 2013;152:9–15.
   PubMed Web of Science ®Google Scholar
• Razavi M, Jamilian M, Karamali M, et al. The effects of vitamin D-K-calcium co-supplementation on endocrine, inflammation, and oxidative stress biomarkers in vitamin D-deficient women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Horm Metab Res. 2016;48:446–451.
   PubMed Web of Science ®Google Scholar
• Maktabi M, Jamilian M, Asemi Z. Magnesium-zinc-calcium-vitamin d co-supplementation improves hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Biol Trace Elem Res. 2017. DOI:10.1007/s12011-017-1085-0
   PubMed Web of Science ®Google Scholar
• Armar NA, McGarrigle HH, Honour J, et al. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril. 1990;53:45–49.
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, Gianaroli L, Magli MC, et al. Transvaginal ovarian drilling: a new surgical treatment for improving the clinical outcome of assisted reproductive technologies in patients with polycystic ovary syndrome. Fertil Steril. 2001;76:812–816.
   PubMed Web of Science ®Google Scholar
• Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356:551–566.
   PubMed Web of Science ®Google Scholar
• Moll E, Bossuyt PMM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332:1485.
   PubMed Web of Science ®Google Scholar